Recruiting
Phase 2

Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)

Sponsor:

Merck Sharp & Dohme LLC

Code:

NCT06482112

Conditions

Metabolic Dysfunction-Associated Steatotic Liver Disease

Non-alcoholic Fatty Liver Disease

Nonalcoholic Fatty Liver Disease

Liver Disease

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Efinopegdutide

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information